Ironwood’s Turnaround Story Hits a Wall as Technical Overheat Triggers Selloff

Ironwood Pharmaceuticals posts $41M Q1 profit vs $37.4M loss last year, but stock drops 11.44% on technical correction. FDA decision on Linzess for children due May 24.

Boston-based Ironwood Pharmaceuticals has swung back into profit, delivering a net income of $41 million for the first quarter of 2026 — a dramatic reversal from the $37.4 million loss posted in the same period last year. Yet investors, rather than celebrating, sent the stock tumbling 11.44 percent to €3.56 on Thursday, punishing a rally that had pushed the shares into dangerously overbought territory.

The disconnect between operational strength and market reaction stems from a technical correction. Before the earnings release, the Relative Strength Index (RSI) had climbed to an extreme reading of 89.3, well above the threshold that typically signals a pullback is due. The stock had earlier hit a fresh 52-week high of €4.36, but the euphoria proved short-lived.

Linzess Powers the Recovery

The turnaround is built squarely on the company’s gastrointestinal drug Linzess. U.S. net sales of the treatment nearly doubled, surging 97 percent to $273 million. Higher pricing and a 5 percent uptick in prescription volumes both contributed to the jump. Ironwood’s collaboration with partner AbbVie also paid off handsomely: the company’s share of profits from the partnership more than tripled to $204.7 million.

Total revenue for the quarter reached $106.5 million, while adjusted EBITDA swung to a positive $76.7 million. The management team has kept its full-year guidance intact, forecasting Linzess U.S. sales of up to $1.175 billion and adjusted EBITDA exceeding $300 million.

FDA Decision Looms

All eyes now turn to the U.S. Food and Drug Administration, which is reviewing an expanded label for Linzess to include young children. A decision is expected by May 24. Approval would open a new patient population and further broaden the drug’s addressable market.

Beyond Linzess, Ironwood is advancing its pipeline candidate Apraglutide. A pivotal Phase 3 study for the treatment of short bowel syndrome is slated to begin in the second quarter of 2026. The company estimates the annual U.S. revenue potential for Apraglutide at more than $700 million.

Balance Sheet Considerations

One overhang for the stock is the maturity of a $200 million convertible note due at the end of 2026. While the company’s improved cash flow provides some cushion, the repayment will require careful capital management.

For now, the technical picture suggests near-term volatility will remain elevated — the stock’s short-term volatility stands above 80 percent. The FDA’s verdict on May 24 is widely seen as the next catalyst that could determine whether Ironwood resumes its upward trajectory or continues to consolidate.